Too much of a good thing can become destructive
Within the intricate machinery of human cells, a protein meant to mend has become an agent of unraveling. Penn State researchers have found that when the EXO1 gene is overproduced in cancer cells — affecting roughly one in four to one in three breast and ovarian tumors, among others — it mimics the destructive signature of BRCA mutations, long considered a distinct inherited condition. This discovery quietly redraws the boundary of who might benefit from existing targeted therapies, suggesting that the map of cancer treatment need not follow the lines of tissue or inheritance, but of molecular behavior.
- A protein designed to repair DNA is instead cutting it apart when overproduced, creating the same dangerous double-strand breaks associated with hereditary BRCA mutations — even in patients who carry no such mutation.
- EXO1 overexpression appears in 20–30% of breast and ovarian cancers and surfaces across melanoma, testicular, cervical, and liver-related cancers, meaning a substantial population of patients may be misclassified as ineligible for powerful targeted treatments.
- Lab tests confirmed that tumors with high EXO1 levels respond with striking sensitivity to olaparib and cisplatin — drugs currently gatekept for BRCA-mutant cancers — raising the possibility that lower doses could shrink tumors with fewer toxic side effects.
- The research team is now preparing clinical trials to test whether these laboratory findings hold in living patients, with EXO1 potentially becoming a biomarker that shifts cancer care from tissue-of-origin logic toward mutation-specific precision.
A protein built to protect DNA is, under certain conditions, destroying it instead. Researchers at Penn State College of Medicine have discovered that when cells overproduce the EXO1 gene, the resulting protein begins cutting apart genetic material indiscriminately — mimicking the cellular damage caused by BRCA mutations, those inherited flaws long associated with hereditary breast and ovarian cancer. The findings, published in Nature Communications, suggest that a meaningful portion of cancer patients may be candidates for drugs they are currently denied.
In healthy cells, EXO1 functions like molecular scissors, carefully trimming and repairing damaged DNA. But in excess, those scissors lose their precision. The protein destabilizes newly synthesized DNA by expanding gaps in single-stranded DNA and degrading reversed replication forks — processes that leave behind the kind of double-strand breaks normally seen only when BRCA genes malfunction. Crucially, the researchers confirmed the damage came from the protein's activity itself: a biochemically disabled version of EXO1, present in cells but unable to interact with other molecules, caused no harm. EXO1 achieves its destruction in partnership with another protein, MRE11, together producing breaks that mirror BRCA pathway failure.
What makes this especially significant is that EXO1 overexpression occurs even when BRCA genes are fully intact and functional. Senior author George-Lucian Moldovan noted that the overexpression does mechanically what BRCA loss does in mutant tumor cells — but through an entirely separate, acquired route. This means patients without any BRCA mutation could still harbor tumors that behave as though they do.
When the team tested existing drugs against EXO1-overexpressing tumors, the results were striking. Both olaparib — a drug designed specifically for BRCA-mutant cancers — and cisplatin, a common chemotherapy, produced hypersensitive responses in these tumors. The implication is that lower doses might achieve comparable results with reduced side effects, and that a far larger population of patients could benefit from therapies currently reserved for a narrower group.
Because EXO1 overexpression is more prevalent across cancer types than BRCA mutations themselves, it holds promise as a biomarker for personalized treatment. Moldovan envisions a future where cancer therapy is guided not by where a tumor originates, but by the specific molecular changes within it. Clinical trials are now being planned to test whether these laboratory insights translate into real benefit for patients whose tumors carry this overlooked molecular signature.
A protein that should be protecting DNA is instead shredding it. Researchers at Penn State College of Medicine have discovered that when cells overproduce a gene called EXO1, the protein it makes begins cutting apart the very genetic material it's designed to repair—and in doing so, it mimics the behavior of BRCA mutations, those inherited genetic flaws linked to hereditary breast and ovarian cancers. The finding, published in Nature Communications, suggests a new way to identify which patients might benefit from drugs currently reserved for a much smaller population.
The EXO1 gene is overexpressed in roughly one in four to one in three cases of breast and ovarian cancer, and also shows up in melanoma, testicular, cervical, and hepatobiliary cancers—those affecting the liver, gallbladder, and bile duct. What makes this discovery significant is not just how common the overexpression is, but what it does. In normal cells, the EXO1 protein functions like molecular scissors, carefully trimming and repairing damaged DNA. But when cells produce too much of it, those scissors start cutting indiscriminately. The protein destabilizes newly synthesized DNA in two main ways: by expanding gaps in single-stranded DNA and by degrading reversed replication forks, both processes that chew away at genetic sequences and leave behind dangerous breaks in the DNA double helix.
Alexandra Nusawardhana, the study's lead author, explained that this accumulation of toxic lesions—particularly double-strand breaks—is what appears to make tumors more sensitive to chemotherapy and increases cell death. The researchers confirmed this wasn't simply a matter of the protein being present; they tested a biochemically disabled version of EXO1 that existed in cells but couldn't interact with other molecules, and found no DNA damage. The damage came specifically from the protein's activity. What's remarkable is that EXO1 achieves this destruction by working in concert with another protein called MRE11, together expanding DNA gaps and creating the kinds of breaks that normally only occur when BRCA genes malfunction.
BRCA genes typically produce proteins that shield DNA during replication. When someone carries a BRCA mutation, cells lose that protection, which can eventually lead to cancer. But the Penn State team found that high levels of EXO1 protein bypass BRCA's defenses entirely, even in cells where BRCA is fully functional and no mutation exists. As George-Lucian Moldovan, the study's senior author, put it: the overexpression does mechanically what the loss of the BRCA pathway does in BRCA-mutant tumor cells. The crucial difference is that EXO1 overexpression is not inherited and is not known to cause cancer on its own—it appears to be an acquired change within tumors.
The practical implications became clear when the researchers tested how EXO1-overexpressing tumors responded to existing cancer drugs. They tested olaparib, a medication designed to target the cellular repair system in BRCA-mutant cancers, and found that tumors with high EXO1 levels were hypersensitive to it, responding exactly like BRCA-mutant cancers would. They also tested cisplatin, a widely used chemotherapy drug, and found similar sensitivity, suggesting that lower doses might achieve the same tumor shrinkage with fewer side effects. These results point toward a significant expansion of who could benefit from these therapies.
Because EXO1 overexpression is more common across tumors than BRCA mutations themselves, it could serve as a biomarker—a measurable indicator that helps predict which patients are likely to respond to certain treatments. This opens the door to more personalized medicine. Moldovan emphasized that the future of cancer treatment should not be based on which tissue a cancer comes from, but on the specific genetic mutations present in each tumor. Since EXO1 overexpression is more prevalent than BRCA mutations, identifying it in a patient's tumor could unlock access to drugs that were previously thought to apply only to a narrower population. The research team is now planning to move forward with clinical trials involving cancer patients whose tumors show EXO1 overexpression, testing whether the laboratory findings translate into real-world benefit.
Notable Quotes
Mechanistically, this overexpression does exactly what the loss of the BRCA pathway does in BRCA-mutant tumor cells— George-Lucian Moldovan, senior author
We shouldn't treat cancers based on what tissue they come from but based on the landscape of the genetic mutations present in the tumors— George-Lucian Moldovan
The Hearth Conversation Another angle on the story
So this protein is supposed to be helpful, but too much of it becomes harmful. How does that happen?
It's like having a tool that works perfectly in the right amount but becomes destructive in excess. EXO1 is designed to trim and repair DNA, but when there's too much, it starts cutting things it shouldn't—expanding gaps and degrading structures that should stay intact. The cell loses control of what gets trimmed.
And this mimics what happens with BRCA mutations, which are inherited. But EXO1 overexpression isn't inherited?
Right. BRCA mutations are something you're born with, passed down through families. EXO1 overexpression happens within the tumor itself—it's acquired, not inherited. But mechanically, the damage it causes looks the same: DNA breaks that make cells vulnerable to certain drugs.
Why does that vulnerability to drugs matter?
Because there are already medications designed to exploit that vulnerability in BRCA-mutant cancers. If EXO1-overexpressing tumors respond the same way, suddenly those drugs could help a much larger group of patients—maybe 20 to 30 percent of breast and ovarian cancers instead of just those with BRCA mutations.
So the real value here is identifying who should get which drug?
Exactly. Instead of treating cancer based on where it started—breast cancer, ovarian cancer—you'd treat it based on what's actually broken inside the tumor. That's the shift toward precision medicine. EXO1 becomes a marker that says: this patient's tumor will respond to this drug.
What happens next?
Clinical trials. The researchers need to test whether what works in the lab translates to actual patients. That's the bridge between discovery and treatment.